Inside the high-stakes gamble to revive tanked biotech Opthea
by Michael Smith · Australian Financial ReviewMichael SmithHealth editor
Jun 28, 2026 – 4.00pm
Jeremy Levin says an age of distrust is killing off the biotech sector. He would know. Levin is the chairman of Opthea, the ASX-listed healthcare hopeful where late-stage clinical trials of the company’s vision-impairment treatment flopped spectacularly last year.
Now he is back, asking investors to give the company a second chance as it pivots from trying to cure a chronic eye disorder that causes blurred vision to combatting a rare lung disease called lymphangioleiomyomatosis.
Loading...
Save
Log in or Subscribe to save article
Share
Copy link
Copied
Copy link
Copied
Share via...
Gift this article
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Already a subscriber? Login
Read More
Michael SmithHealth editorMichael Smith is the health editor for The Australian Financial Review. He is based in Sydney. Connect with Michael on Twitter. Email Michael at michael.smith@afr.com
Latest In Healthcare & fitness
Fetching latest articles